OBJECTIVES: Transcatheter aortic valve implantation (TAVI) does not enable concomitant or simultaneous ascending aortic intervention. This investigation evaluates the safety of TAVI in patients with ascending aortic dilatation and demonstrates mid-term follow-up.
INTRODUCTION
In patients with critical aortic stenosis and ascending aortic aneurysm undergoing open aortic valve replacement (AVR), the current American College of Cardiology (ACC) Foundation guidelines recommend concomitant procedure when the diameter of the ascending aorta is >4.5 cm [1] to avoid the catastrophic events of acute type A ascending aortic dissection or rupture. Since transcatheter aortic valve implantation (TAVI) became an alternative for high-risk patients [2] [3] [4] , more and more patients undergo TAVI and their ascending aorta dilatation, if present, remains untreated. However, in contrast to surgical AVR, the ascending aorta during the TAVI procedure remains untouched and inaccessible to the surgeon. Therefore, the ACC recommendations for concomitant intraoperative repair of the dilatated ascending aorta cannot be applied in TAVI circumstances.
The goal of the present study was to demonstrate the incidence of aortic dilatation in patients undergoing TAVI, to evaluate the procedure's safety in patients with ascending dilatation compared with those with 'normal aorta' and to demonstrate the fate of the unreplaced dilatated ascending aorta after TAVI in mid-term follow-up.
MATERIALS AND METHODS

Patient population
The study population includes the prospective cohort of consecutive patients with severe aortic stenosis screened for TAVI from November 2007 to December 2012 at a single centre. All patients had an increased surgical risk profile due to their comorbidities. The indication to perform TAVI was based on a consensus by the Institutional Heart Team, comprising cardiac surgeons, cardiologists and anaesthesiologists. Among 1143 patients screened for TAVI, a group of 457 (all with tricuspid aortic valve) met the TAVI inclusion criteria. Of these, a total of 98 patients had concomitant ascending aortic dilatation (4.0-5.0 cm) and were compared with 357 patients with non-dilatated ascending aorta (<4.0 cm). Two patients with ascending aortic aneurysm (diameter >5.0 cm) were excluded from the analysis (Fig. 1) .
Transcatheter aortic valve implantation procedure TAVI was performed in a hybrid operating room by the Institutional Heart Team. All patients were under general anaesthesia and had transoesophageal echocardiography (TEE). A perfusionist with a prepared heart-lung-machine was present throughout the procedure in the operating room. Transapical or trans-femoral accesses were gained in the usual fashion [3] . Trans-femoral route as a less invasive delivery option was preferable. All patients underwent implantation of the Edwards Sapien or Sapien XT (Edwards Lifesciences, Irvine, CA, USA) as has been previously described [3] .
Ascending aorta dimension
In all patients ascending aorta diameter was assessed prior to TAVI by computed tomography (CT) angiography, transthoracic echocardiography (TTE) and TEE. At the latest follow-up visit, all patients underwent TTE. The change of proximal ascending aorta diameter was calculated using the echocardiographic data and presented for patients with mild (4.0-4.4 cm) and moderate (4.5-5.0 cm) ascending aortic dilatation.
Patient follow-up
Our follow-up protocol consisted of clinical examination and TTE before discharge, 30 days, 6 months and 1 year after procedure and annually thereafter. The follow-up and surveillance data were obtained by contacting the general practitioners, the patients or their family members. The median follow-up was 14 months (interquartile range, 14 months; 652.2 patient-years) and was 100% complete.
Study end-points
The primary end-point was the rate of aortic dissection and/or rupture during the TAVI procedure. The secondary end-points were in-hospital mortality, 1-year survival and ascending aorta diameter change in follow-up.
Statistical analysis
Normally distributed continuous data are reported as mean (standard deviation) and non-normally distributed data as median (interquartile range). Categorical variables are reported as counts and percentages. For comparison of continuous variables, Student's t-test was applied when normal distribution was present while the Mann-Whitney rank sum test was used when variables were not normally distributed. Comparison of categorical variables was performed using the χ 2 test. P-values are not presented for n ≤ 10 in the subgroup. The Kaplan-Meier method was used to analyse overall survival. All statistical calculations were performed using SigmaPlot 12 (Systat Software, San Jose, CA, USA).
RESULTS
Demographics and clinical presentation
The overall patient cohort was at high risk [STS score, 10 (4.7)%] with a noticeable advanced median age [85.1 (8.6) years], 86 of 455 (18%) patients were over 90 years old and 169 of 455 (37%) patients had previous cardiac surgery. Four hundred and eighteen of 455 patients (92%) were New York Heart Association (NYHA) class III or IV. The gender distribution in all TAVI patients was well balanced with 50% males. However, male sex was more common in patients with dilatated vs non-dilatated ascending aorta, 70 of 98 (71%) vs 158 of 357 (44%, P < 0.001). Overall, the average ascending aorta diameter was greater in men than in women [3.7 (0.7) vs 3.4 (0.6) cm, P < 0.001, Fig. 2 ]. Patients with a dilatated ascending aorta had a higher incidence of coronary artery disease: 53 of 98 (54%) vs 137 of 357 (38%, P = 0.007). There were no other significant differences in clinical presentation (Table 1) .
Aortic valve stenosis characteristics
The mean transaortic gradient was 46 (16) mmHg and aortic valve area 0.6 (0.2) cm 2 in all patients. The incidence of severe aortic valve insufficiency was similar in both groups; however, patients with dilatated ascending aorta had a higher incidence of moderate aortic regurgitation, 24 of 98 (25%) vs 50 of 357 (14%, P = 0.019; Table 2 ).
Periprocedural results
Of the 455 patients scheduled for TAVI, 304 (67%) underwent the procedure via trans-femoral and 151 (33%) via transapical access. Trans-femoral access was more commonly performed in patients with dilatated ascending aorta, 76 of 98 (78%) vs 228 of 357 (64%, P = 0.015). Transaortic gradient after aortic valve implantation was similar in the two groups (Table 3 ). There was no iatrogenic aortic dissection in the entire study cohort. Intraoperative aortic valve annulus rupture with aorto-right ventricular fistula occurred in one 91-year old female patient with mildly dilatated ascending aorta (4.2 cm). Due to serious comorbidities, the patient was managed conservatively and died 6 days later due to the severe right ventricular dysfunction.
In-hospital mortality and follow-up survival
In-hospital mortality for the study cohort was 5% (24 of 455). One-year survival rates in patients with dilatated and nondilatated ascending aorta were 65 of 75 (87%) and 201 of 242 (83%, P = 0.573). Kaplan-Meier survival analysis revealed no significant differences between the two cohorts [dilatated ascending aorta: HR 4.1, 95% confidence interval (CI) 3.7-4.5 years, nondilatated ascending aorta: HR 4.1, 95% CI 3.7-4.4 years; log-rank test P = 0.498, Fig. 3 ].
Fate of the mildly and moderately dilatated ascending aorta
The mean proximal ascending aortic diameter assessed with TTE remained stable at 4.1 (0.2) and 4.7 (0.2) cm in patients with mild (4.0-4.4 cm) and moderate (4.5-5.0 cm) aortic dilatation, respectively, at the median follow-up of 14 months after TAVI. We did not observe an ascending diameter increase of >0.5 cm/year nor an ascending diameter of >5.5 cm in any patients.
Outcome of patients with ascending aortic aneurysm
Two patients with severe aortic stenosis and ascending aortic aneurysm (diameter 5.5 and 5.7 cm, age 87 and 91 years) underwent uncomplicated TAVI. They survived the procedure and expired 7 and 20 months after TAVI due to tumour and heart failure, respectively. 
DISCUSSION
Despite new endovascular advances, open surgical repair still remains the gold standard in the treatment of dilatated proximal aorta. A small number of case reports have described endovascular methods to treat ascending aortopathy [5] [6] [7] , but no specific endovascular device is currently available for such application. In contrast to surgical AVR in patients undergoing the TAVI procedure, concomitant ascending aortic intervention is not feasible. To date, it remains unknown whether endovascular manipulation in the vulnerable dilatated proximal aorta is safe and what the fate of the untreated dilatated ascending aorta is in patients who undergo TAVI. This study is the first evaluation of TAVI procedure results and safety in patients with ascending aortic dilatation. The following points of this investigation will be discussed:
(1) Ascending aortic dilatation is diagnosed in almost one-fourth of patients treated with TAVI. (2) Patients with dilatated ascending aorta undergoing the TAVI procedure are at low risk of intraprocedural adverse aortic events. (3) Both in-hospital mortality and mid-term survival after TAVI are not affected by the presence of ascending aortic dilatation.
Ascending aortic dilatation is a common aortopathy with an incidence rate between 20 and 25% among patients with aortic 10 (6) 10 (5) 10 (6) 0.676 Peak transaortic gradient (mmHg)
18 (10) 17 (9) 18 (11) 0.790 In-hospital length of stay (days) 8 (7) 8 (6) 9 (7) [8] [9] [10] . The results of this study reveal that there is a similar incidence (22%) of ascending aortic dilatation in TAVI patients. The presented TAVI cohort is on average 20 years older and has multiple comorbidities compared with open AVR patients [11] ; thus, a 22% incidence rate of ascending dilatation appears to be relative low. It may result from the fact that some of the patients with aortic valve stenosis (AS) could have been operated on at an earlier age due to concomitant ascending aortic aneurysm when their risk spectrum allowed open surgery. Additionally, some older patients might die due to aortic dissection or rupture. Its incidence remains unknown since there are no autopsy reports on sudden death reasons in older patients. An increasing number of clinical and basic science studies focus on the ascending aortic remodelling in the settings of AS. Recently, histological analysis demonstrated a poorer cohesion of the aortic wall in patients with a post-stenotic dilatated ascending aortopathy (4.0-4.9 cm) than in those with normal aorta [9] . Furthermore, in the same study [9] , there was no difference between the aortic wall cohesion in dilatated aortas and aortic aneurysms (>4.9 cm). The authors postulated that patients with aortic dilatation and aneurysm have a comparable risk of aortic dissection. Another group demonstrated biomolecular changes in the ascending aorta in patients with AS at the time of AVR surgery [12] . Smooth muscle cell apoptosis correlated with aortic dimensions, and there was reduced fibrillar collagen in the setting of aortic dilatation. These findings confirm the structural changes in post-stenotic dilatated aortas and add support to follow the guidelines [1] and replace the ascending aorta when its diameter is >4.5 cm in patients undergoing open AVR surgery. However, in the current era of aortic surgery with very low operative mortality and great spectrum of non-invasive diagnostic tools, the recommendation for concomitant ascending replacement remains under on-going debate. For instance, recently published clinical reports from high-volume centres reported a very low risk of late aortic events (< 2%) in long-term observational studies of patients after AVR surgery with unreplaced ascending aortic dilatation [13, 14] , so that those authors suggested rather a conservative treatment strategy of the ascending aorta at the time of AVR surgery. To date, there are no published results on untreated dilatated ascending aorta in patients who underwent TAVI.
The results of our study demonstrate a very low (1%) risk of intraprocedural adverse aortic events in spite of the presence of dilatated ascending aorta. During the last three decades, improvement in endovascular guidewire techniques has significantly decreased dramatic complications associated with endovascular procedures even in a vulnerable dilatated proximal aorta. In this study, we have demonstrated that improved endovascular manipulations permit a safe TAVI procedure via trans-femoral and transapical access not only in the settings of mildly and moderately dilatated aorta, but also in 2 patients with aortic aneurysm with a diameter of 5.5 cm and greater. Furthermore, in patients with ascending dilatation unsuitable for supra-annularly positioned self-expandable aortic valve prostheses such as the Medtronic CoreValve device, which is anatomically dependent on the ascending aortic dimension because it extends to the ascending aorta to provide coaxial alignment, intraannular implantation of balloon-expandable Edwards Sapien prosthesis can be safely performed.
Several studies have evaluated the natural history of ascending aortic dilatation after open AVR surgery. Progressive dilatation of the ascending aorta has been reported in patients with bicuspid aortic valve [15] . However, in the same study, open AVR prevented further aortic dilatation in patients with tricuspid aortic valve. Other investigators demonstrated an increase in diameter of >0.3 cm in only 27 of 185 (15%) patients (follow-up 30 ± 23 months) with no patients who dilatated beyond 5.5 cm [16] . Although the TAVI patient population is a highly selected group with limited comparison with the open AVR population, our findings showed no increase in the diameter of proximal ascending aorta measured by TTE after the TAVI procedure at a median follow-up of 14 months. One and a half years after the TAVI procedure, survival curves diverge showing superior survival among patients with dilatated ascending aorta. However, due to small number of patients with dilatated ascending aorta, this difference did not reach statistical significance.
This study is limited by several factors. Statistical analysis of risk factors for adverse aortic events could not be performed due to low number of these incidents. The cut-off values of mild (4.0-4.4 cm) and moderate aortic dilatation (4.5-5.0 cm) are arbitrary values. Furthermore, the change in ascending aortic diameter in follow-up must be interpreted with caution, since this analysis was performed according to TTE results, which enable assessment of only the very proximal part of the ascending aorta. Last, we were not able to define the reason for follow-up mortality in the majority of patients, since none of them underwent autopsy and the interview with family members or general practitioners gave us only a plausible cause of death in several cases. Therefore, our study provides information on procedural safety, but is less powerful regarding the long-term outcome in patients with dilatated ascending aorta.
CONCLUSIONS
In current high-risk AS patients classified for the TAVI procedure who have accompanying ascending aortic dilatation (4.0-5.0 cm), TAVI can be performed safely with a very low intraprocedural risk of adverse aortic events. The concomitant ascending aortic dilatation does not affect the mid-term survival in the TAVI population. However, caution should be advised when, in the future, one extrapolates these results to younger patients or patients with aortic valve insufficiency, bicuspid aortic valve or other risk factors for poorer quality of the ascending aorta.
